Exane BNP Paribas Has Just Reaffirmed GBX 5700.00 Target Price Per Shareg

Share

Shire Plc (LON:SHP) Rating Reaffirmed

Shire Plc (LON:SHP) just had their share rating of a ‘”Neutral”‘ issued by research analysts at Exane BNP Paribas, who now has a GBX 5700.00 target PPS on the 26.89 billion GBP market cap company or a 25.52% upside potential. This key information was disclosed to clients in recent note on 7 December.

From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.77. The mean of all analyst targets is GBX 89.63 with a 18.69% above today’s (GBX 4539) stock price. Shire PLC was the topic of 80 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. J.P. Morgan maintained shares on December 4 with “Overweight” rating. Credit Suisse maintained shares with “Neutral” rating and GBX 5400 target share price in a report from a November 4. Bernstein maintained SHP stock in a recent report from November 30 with “Outperform” rating. Barclays Capital maintained the rating on November 3. Barclays Capital has a “Overweight” rating and a GBX 5700 price target on shares. Finally, Berenberg maintained the stock with “Buy” rating in a report issued on a November 16.

Approximately 416,946 shares of stock traded hands. Shire PLC (LON:SHP) has declined 15.50% since May 8, 2015 and is downtrending. It has underperformed by 14.42% the S&P500.

Exane BNP Paribas Has Just Reaffirmed GBX 5700.00 Target Price Per Share on Shire Plc (LON:SHP) stock, While They’ve Also Reiterated Their

Shire plc is a biopharmaceutical company. The company has a market cap of 26.89 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.35 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.

COMMENTS: